A first-in-class EGFR-directed KRAS G12V selective inhibitor is a research paper published in Cancer Cell (2025). On theSindex it has a DataRank of 0.477. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.477
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: R01CA215075
National Cancer Institute
Grant: 1R01CA279532
National Cancer Institute
Grant: 1R44-CA284932
National Cancer Institute
Grant: 1R41CA246848
National Cancer Institute
Grant: P30CA016086
Center for Environmental Health and Susceptibility, University of North Carolina at Chapel Hill
Grant: P30ES010126
Center for Environmental Health and Susceptibility, University of North Carolina at Chapel Hill
Grant: SCR_025231
Duke Cancer Institute
Grant: P30 CA014236
NCI NIH HHS
Grant: R01 CA279532
NIGMS NIH HHS
Grant: R35 GM125005
NCI NIH HHS
Grant: R01 CA258451
NCI NIH HHS
Grant: R41 CA246848
NCI NIH HHS
Grant: R44 CA284932
NHLBI NIH HHS
Grant: T32 HL007057
NCI NIH HHS
Grant: UG1 CA233333
Breast Cancer Research Foundation
North Carolina Biotechnology Center
American Society of Clinical Oncology
University of North Carolina
National Institutes of Health
MeSH Terms
Keywords